Intravacc awarded US$14.6 Million NIH/NIAID contract to develop Intranasal Gonorrhea vaccine
Intravacc awarded US$14.6 Million NIH/NIAID contract to develop intranasal gonorrhea vaccine Bilthoven, The Netherlands, 5 October 2022 – Intravacc, a world leader in translational research and development of preventive and therapeutic vaccines, today announced that it has been awarded a contract with base and options that may total US$14.6 million from the US National Institute…